Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the…
Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the…
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…
Shares of Novartis soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon for $12.9 billion.
Continue reading Novartis Obtains Final Shares of Alcon fo…
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have r…